The hidden gem is Ready to explode Easy & risky trade
Price target as shown on the graph
Loss is 5%
Gain is 40% and above
Does it worth a try! Think about it and trade safe
Biotechnology
Biotech primed for a move higher?This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation here, and I really like the price action on it today. A lot of other sector funds have had mid-day pullbacks, but XBI has maintained its steady upward slope. It has poked above the 20-day EMA. My guess is that this will be green again tomorrow, so I've rolled the dice on a call expiring October 29. I'm also looking for continuation the next two weeks, with a first target of about 131.75.
OPTIlooks like the 5 down are about finished. Would want to see an ABC correction 1st then 5 up impulsive move B4 I could make any targets.
AVDLLooks like a push to the 618 fib retracement might be up next. If we have an impulsive 5 up incoming the chart should look like this IMO.
SPRB - 8M FLOAT - WORTH X2-X3 CURRENT PRICEAll,
I am already scaled in big here. I am without a doubt this stock will at least double.
***KEEP IN MIND THIS IS AN 8M FLOAT COMPANY
1. Do your own DD you will notice all that has really happened is low float short sellers have just railed the price down
2. This companies price targets are insane not to mention 8M float will make this EXPLODE on any good news. The company is already undervalued + postiive news of any kind just blows this baby to the moon. Except here the moon is probably where it SHOULD be.
3. Financially speaking easily in great position no chance of offerings
4. Promising company overall
5. This downtrend looks awful, but is purely short sellers and look at the length of the time on market.
This looks like it may happen soon, but either way I will happily add large position scales into this stock and simply wait. I really think at some point even a year from now we see 20+. The question is do you want to chase stocks daily, weekly or scale in. Either way set alers and volume alerts.
TTOOAppears to have bottomed here and corrections are zig zig patterns 5,3,5 that continue to overlap into each other so I labeled this correction with WXY. Most likely TTOO will push back up from here towards $1.40
$XAIR Symmetrical Triangle BreakBeyond Air has continued a strong uptrend since June. Recently its bin tapering and has shown a symmetrical triangle formation. A Brake out to the upside is likely to continue the uptrend. Watch for a move past the top of the triangle at 11.88 level for conformation and more possible upside. No resistance till 12.50 a high not seen since March 4, 2020
AYTU BioPharma (NASDAQ: $AYTU) Could See Massive Upside 🧪🧪🧪Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.
Bluebird Bio Inc 🧙bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
Here you can see pipeline:
Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-212 Northstar-3 Phase 3 updated at EHA June 11, 2021. 89% (32/36) of evaluable patients achieved transfusion independence (TI) and remain transfusion free (HGB-207, HGB-212)
Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-207 Northstar-2 Phase 3 updated at EHA June 11, 2021. 89% (32/36) of evaluable patients achieved transfusion independence (TI) and remain transfusion free (HGB-207, HGB-212)
Lenti-D (Elivaldogene Autotemcel / Eli-Cel) - ALD-102 Phase 2/3 updated data presented March 15, 2021. 90% of evaluable patients (27/30) alive and free of major functional disabilities at two years follow-up.
Betibeglogene autotemcel (beti-cel) (LentiGlobin) BLA filing to be completed
Betibeglogene autotemcel (beti-cel) (LentiGlobin) - HGB-206 Phase 1/2 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021. Clinical hold lifted June 7, 2021. Data to be presented by end of 2021.
Lenti-D (Elivaldogene Autotemcel / Eli-Cel) - ALD-104 Phase 3 safety data to be presented at EBMT 2020. Noted two adverse events (out of 13 patients) of pancytopenia were considered possibly related to Lenti-D. Phase 3 trial placed on clinical hold - noted August 9, 2021. BLA filing due 2021 subject to resolution of the clinical hold.
ABECMA (idecabtagene vicleucel) Phase 1 data presented at ASH 2020.
bb21217 (CRB-402) Phase 1 data due by end of 2021.
MGTA-145 and plerixafor Phase 2 trial to be initiated 4Q 2021.
Betibeglogene autotemcel (beti-cel) (LentiGlobin) - (HGB-210) Phase 3 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021. Clinical hold lifted June 7, 2021.
VERTEX CAN GO UP Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. Excellent bullish divergence on the monthly. Great time for a long trade on this asset that could attempt a retarget in the $ 240 zone.
How do you like it mate? CFRX What are your thoughts on phase 3 results?
I've been waiting for a long time!
ADVM Technical Analysis 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients.
long idea GNCA 1) Long trend.
2) The price is on the support line.
Open order for Buy 2.04
Target 2,60.
This is not an investment recommendation.
SAVA Stuck At 382It's interesting to see what happens after plotting out fib lines sometimes. SAVA , for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some familiar territory and, so far, is mimicking its trend before the big breakout, which is 382 fib resistance being an issue. Multiple times in the last few days, this area was tested and SAVA was rejected (including 8/3). BUT with the market seemingly building optimism, it could once again be an important area on the chart to be aware of.
"The biotech industry is well known for volatility. When you’re talking about developing life-changing treatments, there’s a lot to account for. The phase trial process brings the potential for big progress but can also put the brakes on otherwise strong rallies in the market. We recently saw this with companies like Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSE: ANVS ), which were also former penny stocks. Both companies developing Alzheimer’s treatments revealed data that didn’t impress the market at all. In response, shares of both stocks plummeted."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NTEC Trying ....AGAINNTEC trying to break and hold above this 786 fib level ....AGAIN. It was a previous area of support leading up to the last sell-off but since breaking below it has remained a sticky level of resistance.
"Aside from the cannabis directive, the company has also built a stronger pipeline for things like cancer. In fact, late last month, a patent abstract from Decoy surfaced. It showed that this was for Decoy’s “Compositions and methods for treatment of cancer using bacteria’ and that the patent was granted. With the latest proposed merger seemingly coming to fruition, this additional piece could give the company more exposure to the mounting cancer trend in the market recently. Shares have catapulted to highs of $17.80 during the week."
Read More about this Decoy/Intec Deal: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
PAVM Wayback MachineHad to go way back to find some levels to plot against and 2017 looks like it's the mark. The interesting part is that this 236 area has been an area of traffic in the past. Considering that PAVM failed to break and hold (for now) once again might reinforce that idea. Prior to reaching those highs, the stock tested this area a few more times but failed at every pass besides 1.
"The progress from Lucid is one aspect that traders are watching with PAVmed. However, an earlier development this summer may have also acted as a catalyst for the record-setting move in 2021. Once again, this involves Lucid’s EsoGuard test. It received a European CE mark certification. This now allows the test to be marketed in numerous European countries...While PAVmed isn’t developing a cancer treatment, the EsoGuard platform is the first step to potential prevention. According to the company, it is the first and only commercially available diagnostic test capable of widespread screening to prevent esophageal cancer deaths through early detection of esophageal precancer and cancer in at-risk chronic heartburn patients."
Quote Source: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
ABIO Caught Between Two FibsOn this episode of "Between Two Fibs" ABIO once again tested the 618 line plotted after using the recent low as the anchor. This has been a failure point 2 other times in the last few weeks but with a little more afternoon momentum, it will be interesting to see if it can break and hold above it. Other than that, the 786 fib appeared to have acted as lower support a few times prior to gapping down recently. With today's big swing, that could be another key level for ABIO to hold at or above.
See More: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
Adverum Biotechnologies Inc 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients.
If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
FXCM's BioTech Basket Short-Term Pullback in Daily StrengthFXCM's BIOTECH basket is in the bullish area on the daily chart on the left. The basket is made up of equal weighting of 2% each in ABBV, AMGN, GILD, CELG and VRTX. A bullish cross of EMAs and stochastic potentially align short-term traders with the daily. If signals occur, movement of stochastic to 80 level and maintenance of that level increase chance of a successful trade in terms of 4 point pattern (red 1234). Trend following indicators may be useful in this case as a potential exit tool. Stop under hourly support in conjunction with risk management techniques.
$IPA ImmunoPreciseGood news and even better volume today. We should see this build a base around $10 - $12. Earnings on the 29th should be interesting.
VWAP rejected and momentum slowed down.
Long $IPA. There is no way big pharma doesn't like this play.
OCGN back to basicsOCGN kind of treading water for now. I think what we need to see are some rock-solid results from COVAXIN, which this rolling submission could be helpful in identifying. The Phase 3 results were interesting. With more warnings coming out about the current SOC EAU vaccines, another option might not be "too late" at this point. But a lot will clearly come down to the results. For now, speculation is probably playing a bigger role as we don't know much more beyond what Ocugen announced this week. Regardless, looking at chart levels, a quick Fib retracement shows a few "pain points" on the chart, namely the 618 fib that has been a frequent resistance level over the last few months.
"On July 2nd, Ocugen reported new evidence from Bharat Biotech. The company shared positive results of its Phase 3 study of COVAXIN™; a whole virion inactivated COVID-19 vaccine candidate. According to the company, it demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%.
“With the Delta variant becoming a dominant strain of COVID-19 in the United States, we believe that the Phase 3 efficacy results reported by Bharat Biotech demonstrate that COVAXIN™ has the potential to become an important option to expand protection against this emerging variant. Combining these data with the only Delta-variant results from a controlled Phase 3 clinical trial, evidence continues to support a favorable benefit-risk profile for COVAXIN™.” - Dr. Bruce Forrest, Acting Chief Medical Officer and a member of the vaccine scientific advisory board of Ocugen. "
Quote Source: 7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
ETF - Go long on ULTRA NASDAQ BIOTECHNOLOGY ($BIB)ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®.
